Another potential reason for the dearth of FDA approvals in 2022 could have been the heat the agency took for its much-criticized 2021 nod for Biogen and Eisai’s Alzheimer’s disease drug Aduhelm.Cancer, as usual, saw the most approvals in 2023 with 16, including four bispec...
Beltran S, de Tomas Labat ME, Ferreras Fernandez P. Primary Ki-1 positive anaplastic large cell non-Hodgkin's lymphoma of the lung. A case study and review of the literature. An Med Interna 2001;18:587-90.Beltran BS, de Tomas LME, Ferreras FP. Primary Ki-1 positive anaplastic large...